Short-term effect of breast conserving surgery combined with intraoperative radiotherapy in 60 patients with breast cancer

doi:10.3877/cma.j.issn.1674-0807.2017.01.003

Abstract

Abstract:

Objective

To evaluate the short-term effect,adverse reaction and cosmetic result of breast conserving surgery combined with INTRABEAM intraoperative radiotherapy in breast cancer patients.

Methods

We retrospectively analyzed the clinical data of 60 patients who underwent breast conserving surgery combined with INTRABEAM intraoperative radiotherapy in Department of Breast Surgery, General Hospital of Lanzhou Military Command from December 2012 to June 2015. All patients received breast conserving surgery,then INTRABEAM intraoperative radiotherapy was given after postoperative pathology confirmed clear surgical margins. The DFS,adverse reaction and cosmetic result were analyzed. Kaplan-Meier method was used to draw DFS curve.

Results

The median follow-up was 24 months (12-42 months). The local recurrence rate was 5% (3/60) two years after operation. The two-year DFS was 95%. There were 8 patients (13.3%, 8/60)with breast fibrosis after radiotherapy,4 (6.7%,4/60) with fat liquefaction and 1 (1.7%,1/60) with breast hematoma. The satisfactory rate of patients in cosmetic effect was 90.0% (54/60), in which the excellent rate and the good rate were 53.3% (32/60) and 36.7% (22/60) respectively.

Conclusion

Breast conserving surgery combined with INTRABEAM intraoperative radiotherapy has beneficial short-term effect, favorable cosmetic result and a few adverse reactions, worthy of clinical practice.

Key words: Breast neoplasms, Mastectomy, subcutaneous, Monitoring, intraoperative, Radiotherapy, computer-assisted

Fan Chai, Qingli Zhao, Fengjun Zhang, Yaqiong Huang. Short-term effect of breast conserving surgery combined with intraoperative radiotherapy in 60 patients with breast cancer[J]. Chinese Journal of Breast Disease(Electronic Edition), 2017, 11(01): 13-18.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhrxbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0807.2017.01.003

https://zhrxbzz.cma-cmc.com.cn/EN/Y2017/V11/I01/13

Figures/Tables 4

References 25

[1]	Lakhani SR,Ellis IO,Schnitt SJ,et al. WHO classification of tumours of the breast [M]. 4th ed. Lyon: IARC Press,2012.
[2]	Edge SB, Byrd DR, Compton CC, et al. AJCC cancer staging handbook [M]. 7th ed. New York: Springer-Verlag,2010.
[3]	Radiation Therapy Oncology Group. RTOG Procedure Manual [EB/OL]. [ 2016-08-12 ]. https:/ /www. rtog. org/LinkClick. aspx?fileticket=WDSHTqDEobQ%3d&tabid=164.
[4]	Keshtgar MR, Vaidya JS, Tobias JS, et al. Targeted intraoperative radiotherapy for breast cancer in patients in whom external beam radiation is not possible[J]. Int J Radiat Oncol Biol Phys, 2011,80(1):31-38.
[5]	Carvalho BP, Frasson AL, Santos MM, et al. Mammography findings following electron intraoperative radiotherapy or external radiotherapy for breast cancer treatment[J]. Eur J Radiol,2011,79(2):e7-10.
[6]	Chua BH, Henderson MA, Milner AD. Intraoperative radiotherapy in women with early breast cancer treated by breast-conserving therapy[J]. ANZ J Surg,2011,81(1/2):65-69.
[7]	Coombs NJ, Coombs JM, Vaidya UJ, et al. Environmental and social benefits of the targeted intraoperative radiotherapy for breast cancer:data from UK TARGIT-A trial centres and two UK NHS hospitals offering TARGIT IORT[J]. BMJ Open,2016,6(5):e010703.
[8]	Vaidya JS, Baum M, Tobias JS, et al. Targeted intra-operative radiotherapy (Targit): an innovative method of treatment for early breast cancer[J]. Ann Oncol,2001,12(8):1075-1080.
[9]	Vaidya JS, Baum M, Tobias JS, et al. The novel technique of delivering targeted intraoperative radiotherapy (Targit) for early breast cancer[J]. Eur J Surg Oncol,2002,28(4):447-454.
[10]	Esposito E, Anninga B, Harris S, et al. Intraoperative radiotherapy in early breast cancer[J]. Br J Surg,2015,102(6):599-610.
[11]	Abbott AM, Dossett LA, Loftus L, et al. Intraoperative radiotherapy for early breast cancer and age: clinical characteristics and outcomes[J]. Am J Surg,2015,210(4):624-628.
[12]	Sperk E, Welzel G, Keller A, et al. Late radiation toxicity after intraoperative radiotherapy (IORT) for breast cancer: results from the randomized phase Ⅲtrial TARGIT A[J]. Breast Cancer Res Treat,2012,135(1):253-260.
[13]	Leonardi MC, Ivaldi GB, Santoro L, et al. Long-term side effects and cosmetic outcome in a pool of breast cancer patients treated with intraoperative radiotherapy with electrons as sole treatment [ J].Tumori,2012,98(3):324-330.
[14]	Grobmyer SR, Lightsey JL,Bryant CM,et al. Low-kilovoltage,singledose intraoperative radiation therapy for breast cancer: results and impact on a multidisciplinary breast cancer program[J]. J Am Coll Surg,2013,216(4):617-623.
[15]	Welzel G, Boch A, Sperk E, et al. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase Ⅲtrial TARGIT-A[J]. Radiat Oncol,2013,8:9.
[16]	Pan L, Zheng W, Ye X, et al. A novel approach of INTRABEAM intraoperative radiotherapy for nipple-sparing mastectomy with breast reconstruction[J]. Clin Breast Cancer,2014,14(6):435-441.
[17]	Vaidya JS, Baum M, Tobias JS, et al. Long-term results of targeted intraoperative radiotherapy (Targit) boost during breast-conserving surgery [J]. Int J Radiat Oncol Biol Phys,2011,81(4):1091-1097.
[18]	Vaidya JS, Wenz F, Bulsara M, et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial[J]. Lancet,2014,383(9917):603-613.
[19]	Silverstein MJ, Fastner G, Maluta S, et al. Intraoperative radiation therapy: a critical analysis of the ELIOT and TARGIT trials. Part 1--ELIOT[J]. Ann Surg Oncol,2014,21(12):3787-3792.
[20]	Ash RB, Williams VL, Wagman LD, et al. Intraoperative radiotherapy for breast cancer: its perceived simplicity[J]. Oncology (Williston Park),2013,27(2):107-113.
[21]	郑一琼, 李席如, 李荣.乳腺癌保乳综合治疗的研究进展[J/CD].中华乳腺病杂志(电子版),2008,2(2):190-201.
[22]	赵惠, 汪延明, 贺青卿,等.INTRABEAM 实施乳腺癌术中放疗系统临床应用观察(附20 例报告)[J]. 现代肿瘤医学,2014,22(12):2972-2974.
[23]	孙春雷, 周士福, 孟东,等. 具备保留乳房条件的早期乳腺癌治疗方式选择[J/CD]. 中华乳腺病杂志(电子版),2013,7(1):31-34.
[24]	王雪霏, 孙强, 茅枫,等. 术中放射治疗应用于乳腺癌保留乳房手术的研究进展[J/CD]. 中华乳腺病杂志(电子版),2012,6(5):553-559.
[25]	朱见, 郑鲁明, 庄大勇,等.IntraBeam 系统在乳腺癌保乳术中应用的安全性研究[J]. 国际外科学杂志,2015,42(3):168-170.

临床病理因素	例数	构成比(%)
年龄
≤50岁	26	43.3
＞50岁	34	56.7
乳腺癌T分期
T₁	36	60.0
T₂	24	40.0
乳腺癌N分期
N₀	46	76.7
N₁	14	23.3
病理类型
浸润性导管癌	52	86.7
其他^a	8	13.3
组织学分级
1级	28	46.7
2级	20	33.3
3级	8	13.3
未知	4	6.7
分子分型
luminal A型	32	53.3
luminal B型	16	26.7
HER-2过表达型	5	8.3
三阴性乳腺癌	7	11.7

临床病理因素	例数	构成比(%)
年龄
≤50岁	26	43.3
＞50岁	34	56.7
乳腺癌T分期
T₁	36	60.0
T₂	24	40.0
乳腺癌N分期
N₀	46	76.7
N₁	14	23.3
病理类型
浸润性导管癌	52	86.7
其他^a	8	13.3
组织学分级
1级	28	46.7
2级	20	33.3
3级	8	13.3
未知	4	6.7
分子分型
luminal A型	32	53.3
luminal B型	16	26.7
HER-2过表达型	5	8.3
三阴性乳腺癌	7	11.7

Please choose a citation manager

Content to export